Ikena Oncology, Inc. (NASDAQ: IKNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Ikena Oncology, Inc. (IKNA)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
IKNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IKNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IKNA alerts
High impacting Ikena Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
IKNA
News
- Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]Yahoo! Finance
- Ikena Oncology, Inc. (NASDAQ: IKNA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $2.00 price target on the stock.MarketBeat
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement [Yahoo! Finance]Yahoo! Finance
- Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private PlacementGlobeNewswire
- Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) [Yahoo! Finance]Yahoo! Finance
IKNA
Earnings
- 8/8/24 - Beat
IKNA
Sec Filings
- 12/31/24 - Form SCHEDULE
- 12/23/24 - Form 425
- 12/23/24 - Form 8-K
- IKNA's page on the SEC website